Join Olema Oncology as a Medical Director to lead clinical development for innovative breast cancer therapies.
Posted by employer 1 day ago
First seen on Joblaze 17 hours ago
Last verified on the company career page 17 hours ago
What you'll build
Must have
Nice to have
Practical constraints
Requirements
Not disclosed in this posting: visa sponsorship.
Benefits
Joblaze summary
In the role of Medical Director, Clinical Development at Olema Oncology, the individual will lead clinical initiatives for palazestrant, focusing on study design, data evaluation, and regulatory engagement. Essential skills include a strong background in oncology, experience in clinical study management, and a thorough understanding of breast cancer treatment paradigms. This position is ideal for an experienced physician leader with a collaborative mindset and a commitment to advancing innovative therapies in a fast-paced environment.
Joblaze insights
Quick facts
From the original posting
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.
Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.
Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year.
Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day.
If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.
About the Role >>> Medical Director, Clinical Development
As the Medical Director, you will serve as an Oncology Physician for palazestrant and play a pivotal role in advancing Olema’s late and early-stage clinical pipeline in breast cancer.
You will contribute to registration-enabling studies by shaping study design, evaluating clinical data, and engaging with regulatory authorities, investigators, and key opinion leaders. Partnering closely with experienced physicians and cross-functional teams, you will ensure scientific rigor, data integrity, and patient-centric decision-making while contributing to biomarker development, publication planning, and external scientific communications.
This is a unique opportunity to contribute at a pivotal moment in the program’s trajectory and support the advancement of therapies for patients with ER-positive, HER2-negative breast cancer.
This role will be based in Cambridge, MA and may require up to 20% travel.
Key Responsibilities
Provide Medical Leadership and Expertise
Design and Deliver High-Impact Clinical Studies
Ideal Candidate Profile: Experienced Oncology Physician Leader
You are an accomplished clinical development physician who thrives on meaningful, challenging work and is motivated by the opportunity to make a lasting impact on patients’ lives. You bring clinical and scientific expertise,]a collaborative mindset, and a hands-on approach to execution. You are also eager to grow professionally, broaden your leadership capabilities, and expand your career by taking on increasing responsibility and helping shape the future of Olema’s clinical development programs.
Knowledge
Experience
Attributes
The base pay range for this position is expected to be $275,000 - $300,000 annually, however the base pay offered may vary depending on location, market, job related knowledge, skills and capabilities, and experience. The total compensation package for this position also includes equity, bonus, and benefits.
#LI-MK1
Important Information >>>
Standard company text repeated across Olema Oncology's postings is omitted here.